Jubilant Pharmova Ltd

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Jubilant Pharmova Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, posted a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales reached a record high, profitability metrics showed contraction, reflecting margin pressures and operational challenges. The company’s recent financial trend has improved from negative to flat, yet the overall outlook remains cautious with a Sell mojo grade.

Jubilant Pharmova Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹16,232 crores, reported a consolidated net profit of ₹119.40 crores for Q4 FY26, marking a dramatic 113.60% sequential jump from ₹55.90 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 22.27% decline from ₹153.60 crores in Q4 FY25, highlighting the uneven nature of the company's profitability trajectory. The stock currently trades at ₹1,005.75, down 0.54% on the day of this analysis.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jubilant Pharmova Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.

Jubilant Pharmova Ltd is rated Sell by MarketsMOJO, with this rating last updated on 10 April 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jubilant Pharmova Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 April 2026, reflecting nuanced shifts across technical indicators and valuation metrics despite ongoing financial challenges. This recalibration follows a detailed analysis of the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer perspective on its current market positioning within the Pharmaceuticals & Biotechnology sector.

Jubilant Pharmova Ltd has exhibited a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a modest day gain of 1.26%, the stock’s broader trend signals caution amid mixed signals from MACD, RSI, and moving averages, underscoring the challenges facing this small-cap pharmaceutical player in a volatile market environment.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

The Sensex gained 2.05% on 24 Mar 2026, yet Jubilant Pharmova Ltd outpaced the broader market with a 7.07% surge, reaching an intraday high of Rs 874.55. This 6.15 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market lift.

Jubilant Pharmova Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Jubilant Pharmova Ltd’s stock declined sharply to a fresh 52-week low of Rs.783.75 on 10 Mar 2026, marking a significant downturn amid broader market volatility and company-specific headwinds. The stock underperformed its sector and broader indices, reflecting ongoing concerns about its financial performance and valuation metrics.

Jubilant Pharmova Ltd’s stock declined to a fresh 52-week low of Rs.786.55 on 9 Mar 2026, marking a significant drop amid broader market weakness and company-specific performance concerns. The stock has been under pressure for the past two sessions, reflecting a cumulative fall of 3.31% during this period.